ライフサイエンスコーパス: amanitin

1 inhibitors actinomycin D, DRB, H7 and alpha-amanitin.

2 inhibition of ongoing transcription by alpha-amanitin.

3 ranscription was globally inhibited by alpha-amanitin.

4 stant to the transcriptional inhibitor alpha-amanitin.

5 the effect with low concentrations of alpha-amanitin.

6 uming transcription in the presence of alpha-amanitin.

7 of transcription as it is resistant to alpha-amanitin.

8 tivity of stalled transcription complexes to amanitin.

9 polymerase II, the subunit that binds alpha-amanitin.

10 age in arrested complexes is not affected by amanitin.

11 stant to the inhibitors rifampicin and alpha-amanitin.

12 A via a specific small-molecule inhibitor, a-amanitin.

13 as does inhibition of transcription by alpha-amanitin.

14 on of endogenous Pol II using a toxin, alpha-amanitin.

15 l chromatin insulators are affected by alpha-amanitin.

16 inished by treatment of the cells with alpha-amanitin.

17 n active transcription and arrested by alpha-amanitin.

18 lectively resistant to inhibition with alpha-amanitin.

19 racts with the transcription inhibitor alpha-amanitin.

20 ex, which is specifically inhibited by alpha-amanitin.

21 scription in Giardia is resistant to 1 mg/ml amanitin.

22 iptional inhibitors, actinomycin D and alpha-amanitin.

23 high concentrations (100 microg/ml) of alpha-amanitin.

24 D-ribofuranosylbenzimidazole (DRB) and alpha-amanitin.

25 merase inhibitors on HDV genome replication: amanitin, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazo

26 oding genes is relatively resistant to alpha-amanitin (50% inhibition = 250 microg alpha-amanitin/ml)

27 hat is resistant to the mushroom toxin alpha-amanitin, a characteristic of transcription by RNA pol I

28 riole overduplication are abrogated by alpha-amanitin, a potent and specific RNA pol II inhibitor.

29 pol II dephosphorylation confirmed by alpha-amanitin, a specific RNA pol II inihibitor, showing pote

30 presence of the translocation blocker alpha-amanitin, a steady state condition is established in whi

31 alpha-Amanitin, a transcription inhibitor, did not suppress cy

32 validated qualitatively for alpha- and gamma-amanitin according to international recommendations.

33 Amanitin also greatly slows pyrophosphorolysis by elonga

34 hibition of zygotic transcription with alpha-amanitin also induced apoptosis.

35 of Pol II is significantly induced by alpha-amanitin, an amatoxin that blocks Pol II elongation and

36 rigera, AMA1 and PHA1, directly encode alpha-amanitin, an amatoxin, and the related bicyclic heptapep

37 ery of a polar cell-impermeable toxin, alpha-amanitin, an inhibitor of RNA polymerase II.

38 ut also provides rapid access to various new amanitin analogues.

39 e II (RNAPII) translocation inhibitors alpha amanitin and 5,6-dichloro-1-beta-D-ribobenzimidazole (DR

40 hepatocytes were also observed in the alpha-amanitin and acetaminophen-induced liver injury mouse mo

41 e show that transcriptional inhibitors alpha-amanitin and actinomycin D specifically disrupt the symm

42 ion factor eIF-4C that is inhibited by alpha-amanitin and correlated with a transient increase in the

43 of G. lamblia RNAP II transcription to alpha-amanitin and found that unlike most other eukaryotes, RN

44 pared with 8-cell embryos treated with alpha-amanitin and MII.

45 In Amanita bisporigera, alpha-amanitin and phallacidin are synthesized as 35- and 34-a

46 alpha-Amanitin and phallacidin are synthesized as proproteins

47 riptional inhibitors actinomycin D and alpha-amanitin and requires the kinase activity of ATM but not

48 manitin but sensitive to 100 microg/ml alpha-amanitin and tagetitoxin, suggesting involvement of RNA

49 e II that is relatively insensitive to alpha-amanitin and that differs from typical eukaryotic RNA po

50 uire an RNA primer, are insensitive to alpha-amanitin, and differ in their ability to displace the no

51 endent RNA polymerases (actinomycin D, alpha-amanitin, and rifampin).

52 localized with RNA polymerase II in an alpha-amanitin- and actinomycin D-sensitive manner.

53 omatography-based assay using the monoclonal amanitin antibody AMA9G3 and liquid chromatography (LC)

54 side triphosphate (NTP) substrates and alpha-amanitin are added to a human RNA polymerase II elongati

55 e of NTPs resume RNA synthesis when NTPs and amanitin are added.

56 Using alpha-amanitin as a dynamic probe of the RNA polymerase II mec

57 d to correlate with the sensitivity to alpha-amanitin, as S. pombe was intermediate between human and

58 nomic HDV RNA was totally inhibited by alpha-amanitin at concentrations as low as 2.5 microg/ml.

59 Of most interest, amanitin at low doses blocked accumulation of HDV RNA-di

60 However, we found that alpha-amanitin-based antibody-drug conjugates are highly effec

61 this proof-of-concept study we grafted an a-amanitin-based SMDC that targets prostate cancer cells o

62 The amanitin motif (amanitin binding site) of Rpb1 from G. lamblia has amino

63 the total synthesis of the death cap toxin a-amanitin but also provides rapid access to various new a

64 ed by co-incubation with picrotoxin or alpha-amanitin but is insensitive to nifedipine, indicating th

65 tant to the RNA polymease II inhibitor alpha-amanitin but is sensitive to short interfering RNA speci

66 of TARE-6 was resistant to 1 microg/ml alpha-amanitin but sensitive to 100 microg/ml alpha-amanitin a

67 Chain elongation with amanitin can continue for hours at approximately 1% of t

68 Here we show that low doses of alpha-amanitin-conjugated anti-epithelial cell adhesion molecu

69 Here, we demonstrate that a-amanitin-conjugated trastuzumab (T-Ama) potentiated the

70 ized by an RNA polymerase resistant to alpha-amanitin, consistent with previously published reports r

71 pHLIP-mediated cytoplasmic delivery of amanitin could create great opportunities to use the tox

72 The major mechanism of amanitin delivery is direct translocation (flip) across

73 rase II inhibition and cytotoxicity with one amanitin derivative of superior RNAP II inhibition.

74 gamma interferon or its inhibition by alpha-amanitin did not alter nucleosome occupancy, positioning

75 of pol I by cycloheximide or pol II by alpha-amanitin did not significantly affect the PNC.

76 ase II in a complex with the inhibitor alpha-amanitin has been determined by x-ray crystallography.

77 Previous clinical applications of alpha-amanitin have been limited owing to its liver toxicity.

78 trace detection of alpha-, beta-, and gamma-amanitin in human urine samples to confirm ingestion, we

79 Transcription inhibition by alpha-amanitin in vitro enhanced pol II ubiquitylation at ubiq

80 icrograms/ml but not 1 microgram/ml of alpha-amanitin indicates transcription of the mouse YRNA genes

81 lly renders Pol II highly resistant to alpha-amanitin, indicating a functional interaction between Hi

82 tion of the GP63 genes is sensitive to alpha-amanitin, indicating that they are transcribed by a diff

83 ription of the ESAG-Is is sensitive to alpha-amanitin, indicating that they are transcribed by a diff

84 ffected by either kinase inhibitors or alpha-amanitin-induced depletion of pol II.

85 ir sensitivity to DRB, indicating that alpha-amanitin induces apoptosis solely by inhibiting RNAP II

86 Additionally, both actinomycin D and alpha-amanitin inhibited the increase in uPA mRNA by PAF.

87 We propose that alpha-amanitin-inhibited Pol II elongation, which is slow and

88 s indicated that this apparent resistance to amanitin inhibition of genomic and antigenomic RNA relat

89 We show by alpha-amanitin inhibition that RNA polymerase II (RNAPII) tran

90 In contrast, 50 microg/ml amanitin inhibits 85% of RNAP III transcription activity

91 in the following bond addition cycle, alpha-amanitin inhibits elongation at each translocation step.

92 alpha-Amanitin insensitivity confirmed that overexpression of

93 trate selectivity, results from direct alpha-amanitin interference with the TL.

94 Although alpha-amanitin interferes with the transcript cleavage stimula

95 We show that pHLIP can deliver alpha-amanitin into cells in a pH-dependent fashion and induce

96 The cyclic octapeptide amanitin is a relatively selective inhibitor of eukaryot

97 The toxin alpha-amanitin is frequently employed to completely block RNA

98 itivity to different concentrations of alpha-amanitin is that expected for human RNA polymerase III;

99 -beta-D-ribofuranosyl-benzimadazole or alpha-amanitin leads to accumulation of cellular p53 protein.

100 as inhibited by a low concentration of alpha-amanitin (<3 microgram/ml) and could be partially restor

101 -amanitin (50% inhibition = 250 microg alpha-amanitin/ml).

102 The amanitin motif (amanitin binding site) of Rpb1 from G. l

103 presence of the translocation blocker alpha-amanitin, NTPs (but not deoxynucleotide triphosphate [dN

104 the effect of the fungus-derived toxin alpha-amanitin on the transcription of protein-coding genes of

105 Treatment of cells with alpha-amanitin or actinomycin D revealed that extension of B2

106 s blocked by cycloheximide, but not by alpha-amanitin or actinomycin D.

107 ating Pol II-DNA complexes arrested by alpha-amanitin or cisplatin lesions, triggering ubiquitination

108 Suppression of POLR2A with alpha-amanitin or small interfering RNAs selectively inhibits

109 Inhibition of transcription using alpha-amanitin, or the dissolution of R loops by transient exp

110 mplexes were slowed by the presence of alpha-amanitin, origin activity depended on the orientation of

111 model and models of acetaminophen and alpha-amanitin poisoning were used.

112 hat is supported by rerefinement of an alpha-amanitin-Pol II crystal structure.

113 Inhibition of Pol II activity using alpha-amanitin reduced expression of a number of Pol III genes

114 udy we carry out a genetic analysis of alpha-amanitin resistance in a population sample of Drosophila

115 pport previous proposals of the mechanism of amanitin resistance in other organisms and provide a mol

116 nserved sites that have been associated with amanitin resistance in other organisms.

117 These observations of amanitin resistance of Giardia RNA polymerase II support

118 Engineered expression of an alpha-amanitin resistance RNAP II gene rendered cells resistan

119 multidrug resistance gene (Mdr65A) in alpha-amanitin resistance.

120 The antigenomic RNA labeling was alpha-amanitin resistant and localized to the nucleolus.

121 s contribute to the difference between alpha-amanitin-resistant and alpha-amanitin-sensitive third ch

122 and could be partially restored by an alpha-amanitin-resistant mutant pol II; however, surprisingly,

123 Using an alpha-amanitin-resistant polymerase, we provide evidence that

124 Utilizing alpha-amanitin-resistant RNA polymerase II mutants with or wit

125 ing plasmid constructs that express an alpha-amanitin-resistant RNAP II subunit with a truncated or f

126 n immunodeficiency virus 1, we used an alpha-amanitin-resistant system developed previously.

127 script cleavage activity which is completely amanitin-resistant; furthermore, pyrophosphorolytic tran

128 ts, and inhibition of transcription by alpha-amanitin resulted in the initiation of replication withi

129 ed with the transcriptional inhibitor, alpha-amanitin, revealed that the symmetry of cell division is

130 The genomic RNA labeling was alpha-amanitin sensitive and more diffusely localized in the n

131 3 and 4.4 loci) whose transcription is alpha-amanitin sensitive.

132 firmed that HDV RNA synthesis had both alpha-amanitin-sensitive and -resistant components.

133 Based on alpha-amanitin-sensitive BrUTP incorporation, transcription in

134 eChip set, we characterized the set of alpha-amanitin-sensitive genes expressed during the 1- and 2-c

135 e between alpha-amanitin-resistant and alpha-amanitin-sensitive third chromosome lines, the underlyin

136 0 intergenic region promoter can drive alpha-amanitin-sensitive transcription at an internal position

137 was functionally sufficient to support alpha-amanitin-sensitive transcription.

138 esent on the MOE430 GeneChip set to be alpha-amanitin-sensitive.

139 nes expressed in the 2-cell embryo are alpha-amanitin-sensitive.

140 A comparison of the alpha-amanitin sensitivity of transcription in naturally occur

141 carried out by an RNA polymerase with alpha-amanitin sensitivity reminiscent of SL RNA synthesis and

142 nscription began, but experiments with alpha-amanitin show that cyclin E degradation is not dependent

143 e 50-amino-acid region thought to bind alpha-amanitin shows that this region of the trichomonad RNA p

144 could be inhibited by low concentrations of amanitin specific for Pol II transcription.

145 t of cells with actinomycin D, DRB, or alpha-amanitin, specific inhibitors of Pol II, disperses ELL a

146 that inhibition of RNAPII activity by alpha-amanitin specifically blocks processing of rRNA.

147 cription in CS-B cells is sensitive to alpha-amanitin, suggesting that it is RNA polymerase II-depend

148 llowing activation but is sensitive to alpha-amanitin, suggesting that polymerase movement is needed

149 ucleotides into RNA in the presence of alpha-amanitin, suggesting that the polymerase I enzyme is par

150 V RNAs have different sensitivities to alpha-amanitin, suggesting that these two strands are synthesi

151 analogue, Asn((N-ethylazide))-S,6'-dideoxy-a-amanitin, suitable for CuAAC conjugation to empower stud

152 polymerase inhibitors tagetitoxin and alpha-amanitin that are consistent with RNA polymerase II tran

153 tional interaction between His1085 and alpha-amanitin that is supported by rerefinement of an alpha-a

154 ,3R,4R)-4,5-dihydroxyisoleucine (DHIle) in a-amanitin, that in turn enables the scalable synthesis of

155 For 70 years, alpha-amanitin, the most cytotoxic peptide in its class, has b

156 the two-cell stage in the presence of alpha-amanitin, this change in transcript abundance is not obs

157 b) antigenomic RNA was not affected by alpha-amanitin to a concentration higher than 25 microgram/ml.

158 nsulin receptors in cells treated with alpha-amanitin to block host cell mRNA synthesis.

159 When treated with alpha-amanitin to inhibit transcription or JQ-1 to inhibit bin

160 ion capability could be tuned by conjugating amanitin to the C-terminus of pHLIP via linkers of diffe

161 ution described nonspecific binding of alpha-amanitin to yeast RNA polymerase II.

162 bit RNA polymerases I, II, and III) or alpha-amanitin (to inhibit RNA polymerases II and III) as well

163 lved in the biosynthesis of the highly toxic amanitin toxin family of macrocycles.

164 s outside the plant kingdom (e.g., the alpha-amanitin toxin gene family in the mushroom, Amanita bisp

165 chemical mutation' tools coupling with alpha-amanitin transcription inhibition assay to systematicall

166 e duplication proceeded undisturbed in alpha-amanitin-treated cells.

167 alpha-Amanitin treatment had no effect on the ratio of phospho

168 gle- and triple-knockdown experiments, alpha-amanitin treatment, transcriptome profiling and chromati

169 e SII-mediated transcript cleavage following amanitin treatment.

170 Apoptosis induced by cycloheximide or alpha-amanitin was blocked by injection of RNA encoding Xenopu

171 Following treatment with alpha amanitin we observed a profound reduction in the occupan

172 by the POP of C. albipes, but a precursor of amanitin (which is not made by C. albipes) was cleaved i

173 eucine (DHIle), an amino acid found in alpha-amanitin, which appears to be critical for toxicity.

174 The addition of alpha-amanitin, which can inhibit transcription, reduced unres

175 pHLIP-SPDP-amanitin, which exhibits 4-5 times higher antiproliferat

176 D-ribofuranosylbenzimidazole (DRB) and alpha-amanitin, which inhibit RNAP II function by two distinct

177 We find that the mushroom toxin alpha-amanitin, which inhibits TL mobility, suppresses the eff

178 Embryos cultured in the presence of alpha-amanitin, which permitted the distinguishing of maternal

179 PADT is inhibited by alpha-amanitin, which presumably blocks the required conformat

180 resistant to induction of apoptosis by alpha-amanitin without affecting their sensitivity to DRB, ind